Mycophenolate mofetil: a new therapeutic option in dermatology
Keywords:
Mycophenolate mofetil, inosine monophosphate dehydrogenase, dermatologyAbstract
Mycophenolic acid (MPA) was introduced in the 1970s as a treatment for psoriasis, it has since been reformulated as mycophenolate mofetil (MMF). With an improved side effect profile and enhanced bioavailability, MMF is a promising drug for immune-mediated skin diseases. It is currently approved for the prevention of organ rejection. Its list of dermatological indications continues to grow. As a noncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), MMF inhibits de novo purine synthesis. Its relative lack of hepatonephrotoxicity and perhaps low risk of carcinogenicity offer important therapeutic advantages. This new formulation showed enhanced bioavailability, tolerability and efficacy. No doubt case reports and case series of MMF therapy dominate the dermatologic literature; preliminary results are sufficiently promising to warrant larger, randomized clinical trials with this emerging therapy.References
Alsberg CL, Black OF. Contribution to the study of maize deterioration; biochemical and toxicological investigations of Penicillium puberulum and Pencillium stoloniferum. Bull Burl Anim Ind. US Dept Agr 1913; 270: 1-47.
Abraham EP. The effect of mycophenolic acid on the growth of Staphylococcus aureus in heart broth. Biochem J 1945; 39: 398-404.
Abrams R, Bentley M. Biosynthesis of nucleic acid purines. I. Formation of guanine from adenine compounds in bone marrow extracts. Arch Biochem 1995; 56: 184-95.
Cline JC, Nelson JD, Gerzon K, Williams RH, Delong DC. In vitro antiviral activity of mycophenolic acid and its reversal by guanine-type compounds. Appl Microbiol 1969; 18: 14-20.
Kosugi Y, Saito Y, Mori S. Antiviral activities of mizoribine and other inosine monophosphate dehydrogenase inhibitors against several ortho- and paramyxoviruses. Antiviral Chem Chemother 1994; 5: 366-71.
Liu V, Mackool BT. Mycophenolate in dermatology. J Dermatol Treat 2003; 14: 203-11.
Assmann T, Ruzicka T. New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications. Clin Dermatol 2002; 20: 505-14.
Jones EL, Epinette WW, Hackney VC et al. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 1975; 65: 537-42.
Lee WA, Gu L, Miksztai AR et al. Bioavailability improvement of mycophenolic acid through ammo ester derivatization. Pharm Res 1990; 7: 161-6.
Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10: 77-84.
Mehling A, Grabbe S, Voskort M et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000; 165: 2374-81.
Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429-55.
Nousari HC, Sragovich A, Kimyai-Asadi A et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999; 40: 265-8.
Geilen CC, Tebbe B, Garcia Bartels C et al. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br J Dermatol 1998; 138: 1101-2.
Haufs MG, Beissert S, Grabbe S et al. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol 1998; 138: 179-81.
Tong DW, Walder BK. Widespread plaque psoriasis responsive to mycophenolate mofetil. Australas J Dermatol 1999; 40: 135-7.
Grundmann-Kollrnann M, Mooser G, Schraeder P et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000; 42: 835-7.
Geilen CC, Arnold M, Orfanos CE. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol 2001; 144: 583-6.
Zhou Y, Rosenthal D, Dutz J, Ho V. Mycophenolate mofetil (CellCept®) for psoriasis: A two-center, prospective, open-label clinical trial. J Cutan Med Surg 2003; 7: 193-7.
Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000; 143: 385-91.
Grundmann-Kollmann M, Kaufmann R, Zoilner TM. Treatment of atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2001; 145: 351-2.
Mimouni D, Anhalt GJ, Cummins DL et al. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol 2003; 139: 739-42.
Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999; 135: 54-6.
Farley-Li J, Mancini AJ. Treatment of linear IgA bullous dermatosis of childhood with mycophenolate mofetil. Arch Dermatol 2003; 139: 1121-4.
Nousari HC, Griffin WA, Anhalt GJ. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol 1998; 39: 497-8.
Katz KH, Marks JG Jr, Helm KF. Pemphigus foliaceus successfully treated with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol 2000; 42: 514-5.
Megahed M, Schmiedeberg S, Becker J, Ruzicka T. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol 2001; 45: 256-9.
Williams JV, Marks JG Jr, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol 2000; 142: 506-8.
Schattenkirchner S, Eming S, Hunzelmann N et al. Treatment of epidermolysis bullosa acquisita with my cophenolate mofetil and autologous keratinocyte grafting. Br J Dermatol 1999; 141; 932-3.
Sievers TIM, Rossi S3, Ghobrial RM et al. Mycophenolate mofetil. Pharmacotherapy 1997: 17: 1178-97.
Repchinsky C. Compendium of pharmaceuticals and specialties: the Canadian drug reference for health professionals. Ottawa: Canadian Pharmacists Association (2004).
Kitchin JE, Pomeranz MK, Pak G et al. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 1997; 37: 445-9.
